BioLineRx (BLRX) EV to EBITDA (2015 - 2026)
Analysis
BioLineRx (BLRX) EV to EBITDA (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 10 | BioLineRx | 6.53 Bn | 6.53 Bn | 235,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2,276.94 |
| Mar 31, 2026 | -1,994.57 |
| Dec 31, 2025 | -2,131.20 |
| Sep 30, 2025 | -2,048.00 |
| Jun 30, 2025 | -2,365.26 |
| Mar 31, 2025 | -1,472.20 |
| Dec 31, 2024 | -2,269.44 |
| Sep 30, 2024 | -4,351.43 |
| Jun 30, 2024 | -4,284.46 |
| Mar 31, 2024 | -10,089.39 |
| Dec 31, 2023 | -3,673.10 |
| Sep 30, 2023 | -5,435.42 |
| Jun 30, 2023 | -5,954.27 |
| Mar 31, 2023 | -3,705.29 |
| Dec 31, 2022 | -2,587.61 |
| Sep 30, 2022 | -3,750.57 |
| Jun 30, 2022 | -4,810.95 |
| Mar 31, 2022 | -8,038.51 |
| Dec 31, 2021 | -8,835.95 |
| Sep 30, 2021 | -4,463.68 |